Compare ALAR & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALAR | INTS |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 13.7M |
| IPO Year | 2018 | 2021 |
| Metric | ALAR | INTS |
|---|---|---|
| Price | $1.37 | $3.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $16.00 | ★ $19.33 |
| AVG Volume (30 Days) | ★ 48.2K | 21.1K |
| Earning Date | 11-25-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.89 | N/A |
| Revenue Next Year | $26.13 | N/A |
| P/E Ratio | $44.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.16 | $0.22 |
| 52 Week High | $16.56 | $8.06 |
| Indicator | ALAR | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 31.39 | 37.58 |
| Support Level | $1.16 | $0.28 |
| Resistance Level | $2.10 | $5.09 |
| Average True Range (ATR) | 0.13 | 0.33 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 15.25 | 16.21 |
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment: web data collection. Geographically, it derives maximum revenue from China, followed by the United States, Europe, Hong Kong, Asia-Pacific, U.K. Virgin Islands, Israel, United Arab Emirates, Middle East & Africa and other.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.